Showing 5091-5100 of 5693 results for "".
- Eyevance Pharmaceuticals launches Tobradex ST in the United Stateshttps://modernod.com/news/eyevance-pharmaceuticals-launches-tobradex-st-in-the-united-states/2477333/Eyevance Pharmaceuticals has announced the US launch of Tobradex ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% following the company’s acquisition of the product in late 2019. Tobradex ST is an FDA approved, fixed-dose topical antibiotic and corticosteroid combination indicated f
- Zeiss Concludes Acquisition of Saxonia Systems and Creates Carl Zeiss Digital Innovation in Dresden, Germanyhttps://modernod.com/news/zeiss-concludes-acquisition-of-saxonia-systems-and-creates-carl-zeiss-digital-innovation-in-dresden-germany/2477335/Zeiss has concluded its acquisition of Saxonia Systems AG, a specialist for customized software solutions. The fully acquired company will now operate as Carl Zeiss Digital Innovation. The new unit will support the Zeiss segments with their digital projects and play a leading role in terms of inn
- VEO Ophthalmics to Support The Masket Foundation to Raise Awareness of Aniridiahttps://modernod.com/news/veo-ophthalmics-to-support-the-masket-foundation-to-raise-awareness-of-aniridia/2477331/VEO Ophthalmics announced that, in honor of Rare Disease Day, it is collaborating with the Masket Foundation to raise awareness of aniridia and treatment options for aniridia. Aniridia is a serious ophthalmic rare disease in which a patient’s iris does not develop properly. VEO Ophthalmics is the
- Penn Medicine Study Finds Missing One Eye Appointment Can Lead to Vision Loss in Elderlyhttps://modernod.com/news/penn-medicine-study-finds-missing-one-eye-appointment-can-lead-to-vision-loss-in-elderly/2477319/A Penn Medicine study discovered that missing one ophthalmology appointment within a 2-year period could cause dec
- Companies in US Drug Supply Chain Unveil Pilot Project to Track Counterfeit Medicineshttps://modernod.com/news/companies-in-us-drug-supply-chain-unveil-pilot-project-to-track-counterfeit-medicines/2477315/Several companies, including Pfizer, GlaxoSmithKline, Roche, Eli Lilly, Novartis, Sanofi, Novo Nordisk, Amgen and Gilead Sciences, have created a blockchain-based platform to track prescription products across the supply chain in an effort to better stem the flow of counterfeit medicines, a
- Eyevance Pharmaceuticals Appoints Julie Speed as Chief Commercial Officerhttps://modernod.com/news/eyevance-pharmaceuticals-appoints-julie-speed-as-chief-commercial-officer/2477316/Eyevance Pharmaceuticals has appointed Julie Speed to the position of Chief Commercial Officer. In her new role, Ms. Speed will be responsible for developing the commercial strategy and overseeing the growth of Eyevance’s product portfolio, including Flarex (fluorometholone acetate) 0.1%, Freshk
- Verana Health Appoints Veteran Cardiologist Matthew Roe, MD, as Chief Medical Officerhttps://modernod.com/news/verana-health-appoints-veteran-cardiologist-matthew-roe-md-as-chief-medical-officer/2477312/Verana Health announced the appointment of Matthew Roe, MD, MHS, as Chief Medical Officer. A cardiologist and clinical researcher, Dr. Roe joins Verana Health after spending over 2 decades at the Duke University Schoo
- HumanOptics Receives CE Mark for Trifocal Lens Triva-aAhttps://modernod.com/news/humanoptics-receives-ce-mark-for-trifocal-lens-triva-aa/2477310/HumanOptics AG has received CE marking and approval in the European market for its new trifocal lens Triva-aA. Triva-aA is the first multifocal lens from HumanOptics with three focal points. Its optimized design enables patients to enjoy good vision not only at long and near distances, but
- Myopia Management Focus of Pipeline Expansion for Leo Lens Pharmahttps://modernod.com/news/myopia-management-focus-of-pipeline-expansion-for-leo-lens-pharma/2477307/Leo Lens Pharma (formerly DBA as Leo Lens Technology Co.) announced it received a notice of allowance from the United States Patent and Trademark Office for a patent for the use of its proprietary MediPrint process to manufacture a contact lens capable of providing enhance
- Palatin Technologies Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial With PL9643https://modernod.com/news/palatin-technologies-announces-first-patient-enrolled-in-dry-eye-disease-phase-2-clinical-trial-with-pl9643/2477303/Palatin Technologies announced that it has enrolled the first patient in a phase 2 clinical trial of topical PL9643, a melanocortin 1/5 receptor (MC1/5r) agonist, for the treatment of dry eye disease (DED). “We are pleased to initiate this phase 2 study of PL9643 exploring treatment